Announced Fri, 26 Jun · 12:37 IST
Marksans Pharma resubmits FY26 results; standalone PAT up 60 percent
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+7.1%1-day move
₹258.00
prior close
₹256.09
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.9+0.9+1.1+2.5+7.1+3.9+3.6+2.6+0.8+2.3+3.3———
Up moveDown movePending
AI summary
Marksans Pharma resubmitted FY26 audited results in machine readable format after NSE flagged earlier filing. Standalone revenue rose 14 percent to 13,415 million and PAT jumped 60 percent to 3,007 million. Consolidated revenue grew 13 percent to 29,509 million with PAT up 10 percent at 4,201 million. Board recommended 0.90 per share final dividend. Two new subsidiaries formed in Ireland and Canada. Auditor gave clean unmodified opinion.
Likely market impact
Strong earnings growth and 90 percent dividend are positive for shareholders. Resubmission was a formatting fix, not a financial issue.